Jci_page_head_homepage_01 Jci_page_head_homepage_02
Valeriya Lyssenko, Roberto Lupi, Piero Marchetti, Silvia Del Guerra, Marju Orho-Melander, Peter Almgren, Marketa Sjögren, Charlotte Ling, Karl-Fredrik Eriksson, υsa-Linda Lethagen, Rita Mancarella, Göran Berglund, Tiinamaija Tuomi, Peter Nilsson, Stefano Del Prato, Leif Groop
Published in Volume 117, Issue 8
J Clin Invest. 2007; 117(8):2155–2163 doi:10.1172/JCI30706
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Insulin secretion according to different TCF7L2 rs7903146 genotypes or haplotypes.

(A) Insulinogenic index, i.e., incremental (40-minute) insulin response to oral glucose (Malmö cohort; n = 1,038). (B) Disposition index represents the insulinogenic index adjusted for insulin sensitivity by the HOMA index (Malmö cohort; n = 1,038). (C) Change in insulin secretion (disposition index) over time in subjects who converted to T2D (Botnia cohort, n = 120; n = 420 observations). (D) AIR to arginine at basal level (5 mmol/l) and 14 and 28 mmol/l of glucose according to TCF7L2 rs7903146 genotypes in subjects with IGT/T2D (Malmö cohort; n = 130). (E) AIR to arginine at 14 mmol/l of glucose according to TCF7L2 rs7903146 genotypes in subjects with IGT/T2D. (F) AIR to arginine at 28 mmol/l of glucose according to TCF7L2 rs7903146 genotypes in subjects with IGT/T2D. Bars represent mean ± SEM. Blue lines represent non-risk and red lines risk genotype carriers of rs7903146 in TCF7L2.